Levosimendan, an investigational treatment for pulmonary hypertension and heart failure with preserved ejection fraction, or PH-HFpEF — which…
Articles by Marisa Wexler, MS
In late July, the U.S. Food and Drug Administration (FDA) approved a new formulation of Janssen‘s Uptravi (selexipag) for…
The U.S. Food and Drug Administration (FDA) has approved an intravenous form of Uptravi (selexipag) — one infused directly into the…
A protein called TIFA is elevated in the blood cells of people with pulmonary arterial hypertension (PAH), suggesting this…
An upcoming series of educational virtual events for people with pulmonary arterial hypertension (PAH) and their caregivers will offer…
Dosing has begun in a clinical trial testing AER-901, Aerami Therapeutics‘ inhaled formulation of imatinib, which is being investigated…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PT001, an investigational treatment for pulmonary arterial…
A new metric for assessing cardiac health, called pulmonary artery proportional pulse pressure or PAPP, could help to identify people…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for…
Sandoz‘s generic treprostinil injection now is available for subcutaneous (under-the-skin) administration to treat pulmonary arterial hypertension (PAH), the…
A new analysis suggests that the doses of rodatristat ethyl — an investigational therapy for pulmonary arterial hypertension…
An updated application has been filed with the U.S. Food and Drug Administration (FDA), again asking that LIQ861Â be approved…